- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Standard of Care
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
- Interventions
- [¹⁴C]Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 891 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 40
- States / cities
- Alhambra, California • Azusa, California • Bakersfield, California + 37 more
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Placebo, Etelcalcetide
- Drug
- Lead sponsor
- KAI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Cypress, California • Shreveport, Louisiana • Houston, Texas
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 45
- States / cities
- Mobile, Alabama • Azusa, California • Beverly Hills, California + 42 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Alhambra, California • Azusa, California + 64 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 41
- States / cities
- Azusa, California • Bakersfield, California • Chula Vista, California + 37 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- KAI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 13
- States / cities
- Azusa, California • Costa Mesa, California • Lynwood, California + 9 more
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri